HSGC(600774)2024-07-14 07:34Financial Performance - The company expects a net profit attributable to shareholders of approximately 8 million yuan for the first half of 2024, a decrease of about 40.21 million yuan compared to the same period last year, representing a year-on-year decline of approximately 83.41%[4] - The expected net profit attributable to shareholders, after deducting non-recurring gains and losses, is projected to be around -4.5 million yuan, a decrease of about 40.81 million yuan compared to the same period last year, indicating a year-on-year decline of approximately 112.39%[4] - In the first half of 2023, the company achieved a net profit attributable to shareholders of 48.21 million yuan, with a net profit of 36.31 million yuan after deducting non-recurring gains and losses[4] Factors Affecting Performance - The decline in performance is primarily attributed to the impact of the main business, including reduced profits from subsidiaries due to centralized procurement and rising raw material prices[5] - The subsidiary Chongqing Dikang Traditional Chinese Medicine Co., Ltd. experienced lower sales revenue in the first half of the year due to resuming operations, coupled with high fixed costs[6] - The commercial sector's profitability has declined, contributing to the overall reduction in profits[6] Market Recovery - The exhibition sector has seen a gradual market recovery, resulting in profits increasing compared to the same period last year[6] Forecast and Caution - The company emphasizes that the performance forecast is based on preliminary calculations and has not been audited by registered accountants[3] - Investors are advised to be cautious as the forecast data is subject to change and the final financial data will be disclosed in the official half-year report[3] - The company has not identified any significant uncertainties that could impact the accuracy of this performance forecast[3]